Biotechnology BioNTech and partner Pfizer on Friday announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB) that shows the antibodies from people who have received the companies’ COVID-19 vaccine, BNT162b2, effectively neutralize SARS-CoV-2 with a key mutation that is also found in two highly transmissible strains. 11 January 2021